Amgen: Collateral Damage
JHVEPhoto/iStock Editorial via Getty Images
A few days ago, I published an AbbVie (ABBV) article titled “AbbVie: The Humira Situation Remains Scary”. In that article, I covered the main implications (for AbbVie) of Humira’s impending (2023) biosimilar competition…
